Litcius/Paper detail

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial

Andreas Glenthøj, Eduard J. van Beers, Hanny Al‐Samkari, Vip Viprakasit, Kevin H.M. Kuo, Frederic Galactéros, Satheesh Chonat, John B. Porter, Erin Zagadailov, Rengyi Xu, Abdulafeez Oluyadi, Peter Hawkins, Sarah Gheuens, Vanessa Beynon, Wilma Barcellini

2022The Lancet Haematology48 citationsDOI

Topics & Concepts

MedicineOpen labelPyruvate kinaseClinical trialInternal medicinePediatricsSurgeryMetabolismGlycolysisErythrocyte Function and PathophysiologyBlood transfusion and managementPlatelet Disorders and Treatments
Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial | Litcius